Company intelligence / Profile preview

Combinostics

Tampere, Finland

Ownership: Private
Development stage: Other

Overview

Combinostics markets CE-marked / commercial AI-driven brain MRI quantification and clinical decision support software (cNeuro cMRI and cNeuro cDSI) used for early detection, differential diagnosis, and management of major neurodegenerative and other neurological disorders; no drug or interventional clinical trial pipeline is reported, as the offering is software-based diagnostic decision support.[1][3][7]

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapySoftware as a medical device
Industry: Digital Health Medical Devices

Partnerships

Participation in PROMINENT, a collaborative pan-European digital precision medicine platform for neurodegenerative diseases, involving multiple academic and clinical partners[6]

Beyond the preview

Go deeper on Combinostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Combinostics.

Explore the full profile